High Throughput Screening for Specific Inhibitors and Modulators of A Novel Potas

Lieber Institute, Inc., Baltimore MD

Investigators

Linked publications & trials

Abstract

DESCRIPTION (provided by applicant): High Throughput Screening for Specific Inhibitors and Modulators of A Novel Potassium Channel KCNH2 3.1 Associated with Risk for Schizophrenia and its treatment Abstract A recently discovered KCNH2 3.1 potassium channel, a brain selective isoform of the hERG1 potassium channel, has been shown to be increased in the brains of patients with schizophrenia, a genetic risk factor for the emergence of schizophrenia and to affect neuronal cell activity and brain physiology. Because many available antipsychotic drugs bind to know Herg1 channels, the discovery of the novel isoform offers a potential new target for the development of antipsychotic drugs without cardiac side effects. This proposal will use the available Herg1 channel high throughput thallium flux assay to screen compounds for channel modulating activity in a cell line expressing the novel isoform of the hERG channel. The wild type hERG channel will also be screened in parallel to help define the selective modulators of this KCNH2 3.1 potassium channel. The resulting compounds will be validated in electrophysiology experiments. The availability of animal models will allow future testing in vivo for effects on memory and other aspects of animal physiology linked with psychosis.